Higher abatacept exposure after transplant decreases acute GVHD risk without increasing adverse events

Takuto Takahashi(Dana-Farber/Boston Children's Cancer and Blood Disorders Center), Leslie S. Kean(Boston Children's Hospital), Michael A. Pulsipher(Primary Children's Hospital), Mahmoud Al‐Kofahi(University of Minnesota), Brandi Bratrude(Boston Children's Hospital), Kayla Betz(Boston Children's Hospital), Nosha Farhadfar(University of Florida Health), Andrew C. Harris(Primary Children's Hospital), Michael Grimley(Cincinnati Children's Hospital Medical Center), Muna Qayed(Emory University), Alison Yu(Boston Children's Hospital), Roger Giller(Center for Cancer and Blood Disorders), Amelia Langston(CancerCare Manitoba), Bruce R. Blazar(University of Minnesota Medical Center), John Horan(Emory University), Sung Won Choi(University of Michigan), Yvonne Suessmuth(Emory University), Kirk R. Schultz(University of British Columbia), David A. Jacobsohn(Children's National), Mutaz M. Jaber(University of Minnesota), Nahal Lalefar(University of California, San Francisco), Gregory A. Yanik(University of Michigan), Aleksandra Petrović(Seattle Children's Hospital), Shalini Shenoy(Washington University in St. Louis), Jeffrey Davis(BC Children's Hospital), Benjamin Watkins(Emory University), Christine Duncan(Dana-Farber/Boston Children's Cancer and Blood Disorders Center), Donna Neuberg(Otsuka (Japan))
Blood
June 15, 2023
Cited by 16


Related Papers